7 completed, 3 terminated, 1 not yet recruiting, 1 recruiting. 13 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 7, Terminated 3, Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow LPS: new trials by email Literature Review of LPS trials Research Report on LPS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brain Biomarker on Inflammation Response LPS, Placebo - Schizophrenia | Phase 1 | Withdrawn | University of Maryland, Baltimore | 2025-01-01 | 2023-12-05 | |
| Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma Lipopolysaccharides - Asthma; Eosinophilic, Asthma | Phase 1 | Not yet recruiting | National Jewish Health | 60 | 2024-04-01 | 2024-02-21 |
| Neural Response to Inflammatory Challenge in Major Depressive Disorder LPS, Saline - Major Depressive Disorder | Phase 1 / Phase 2 | Recruiting | Laureate Institute for Brain Research, Inc. | 180 | 2021-05-15 | 2026-04-21 |
| First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699 Placebo, GSK3358699, GM-CSF - Arthritis, Rheumatoid | Phase 1 | Terminated | GlaxoSmithKline | 48 | 2018-03-13 | 2020-12-02 |
| Imaging the Neuroimmune System in PTSD Lipopolysaccharide - Post Traumatic Stress Disorder | Phase 1 | Completed | Yale University | 34 | 2017-03-28 | 2024-12-09 |
| Adrecizumab-LPS Study Endotoxin, Placebo, Adrecizumab - Healthy Volunteers | Phase 1 | Completed | Adrenomed AG | 24 | 2017-01-04 | 2021-02-01 |
| Dose-Related Inflammatory Effects of Intravenous Endotoxin in Humans Endotoxin, Placebo - Healthy | Phase 1 | Completed | Robert J Noveck, M.D. | 23 | 2016-08-01 | 2017-04-11 |
| Neuroimmune Response to Lipopolysaccharide Lipopolysaccharide - Healthy | Phase 1 | Completed | Yale University | 27 | 2014-03-25 | 2022-07-19 |
| A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model PF-06282999, Placebo, LPS - Healthy | Phase 1 | Terminated | Pfizer | 23 | 2014-03-01 | 2016-08-02 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057 GSK1995057, bronchoalveolar lavage, LPS - Respiratory Disorders | Phase 1 | Completed | GlaxoSmithKline | 53 | 2012-03-28 | 2019-06-27 |
| Ethnic Differences in the Inflammatory Response in Systemic Inflammation LPS - Endotoxemia | Phase 1 | Completed | Medical University of Vienna | 32 | 2006-01-01 | 2006-09-13 |
| Response of Airway Cells to 20,000 EU of Endotoxin in Normal Adults Clinical Center Reference Endotoxin (CCRE) - Healthy Controls | Phase 1 | Terminated | University of North Carolina, Chapel Hill | 26 | 2003-08-01 | 2012-10-08 |
| Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults Clinical Center Reference Endotoxin (CCRE) - Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Seasonal | Phase 1 | Completed | University of North Carolina, Chapel Hill | 11 | 2002-10-01 | 2009-12-09 |
Asthma (2) · Arthritis, Rheumatoid (1) · Depressive Disorder, Major (1) · Endotoxemia (1) · Hypersensitivity (1) · Infections (1) · Lung Injury (1) · Pulmonary Eosinophilia (1) · Respiration Disorders (1) · Rhinitis, Allergic (1) · Rhinitis, Allergic, Perennial (1) · Rhinitis, Allergic, Seasonal (1) · Schizophrenia (1) · Stress Disorders, Post-Traumatic (1)
GlaxoSmithKline (2) · University of North Carolina, Chapel Hill (2) · Yale University (2) · Adrenomed AG (1) · Laureate Institute for Brain Research, Inc. (1) · Medical University of Vienna (1) · National Jewish Health (1) · Pfizer (1) · Robert J Noveck, M.D. (1) · University of Maryland, Baltimore (1)
United States (8) · United Kingdom (2) · Austria (1) · Netherlands (1)
Kelly Cosgrove, PhD (2) · Christa Firbas, MD (1) · David B Peden, MD, MS (1) · David Peden, MD (1) · L E Hong, M.D. (1) · Peter Pickkers, MD, PhD (1) · Robert J Noveck, MD, PhD (1)
1RC1ES018417 (1), 2017 (1), R01MH110674 (1)